ANI Pharmaceuticals (NASDAQ:ANIP) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Guggenheim restated a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Canaccord Genuity Group began coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $106.83.

ANI Pharmaceuticals Stock Down 5.3%

Shares of ANIP opened at $78.25 on Friday. The firm has a market cap of $1.78 billion, a P/E ratio of 16.86 and a beta of 0.44. ANI Pharmaceuticals has a 12-month low of $70.15 and a 12-month high of $99.50. The company’s 50-day moving average price is $81.02 and its 200 day moving average price is $79.37. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 2,772 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total value of $220,374.00. Following the sale, the senior vice president directly owned 78,696 shares in the company, valued at $6,256,332. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen P. Carey sold 3,313 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total value of $284,918.00. Following the sale, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 88,029 shares of company stock valued at $6,954,472 over the last ninety days. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ANIP. Deutsche Bank AG acquired a new position in ANI Pharmaceuticals in the second quarter valued at approximately $26,775,000. Rice Hall James & Associates LLC acquired a new stake in ANI Pharmaceuticals during the second quarter worth approximately $2,364,000. Persistent Asset Partners Ltd acquired a new stake in ANI Pharmaceuticals during the second quarter worth approximately $76,000. State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $86,000. Finally, Walleye Capital LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $8,784,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.